|
Drug firms are likely to earn profits from new diet
pills. Acomplia, or rimonabant, a diet pill by Sanofi-Aventis
which could be approved by U.S. regulators as early as next
month, is the first of a new wave of treatments that may spell
fat profits for some pharmaceutical companies. This diet drug
is going to prove immensely beneficial for millions of people
suffering form obesity.
Apart from Acomplia, two more experimental drugs from Arena
Pharmaceuticals Inc and Alizyme Plc, with different mechanisms
of action, have also produced promising clinical results in
recent weeks, prompting some investors to start laying big
bets on these two weight loss drugs. Once approved, these
drugs will provide weight loss relief alike other diet pills
such as Phentermine.
Read the complete news article here:
http://today.reuters.com/news/home.aspx
|
